Adjuvant hormonal therapy immediately after radical surgery for high-risk organ-confined or locally advanced prostate cancer.
- Author:
Zhao-Long GUAN
1
;
Liang HUANG
;
Rui-Zhe ZHAO
;
Gong CHENG
;
Chao QIN
;
Peng-Fei SHAO
;
Jie LI
;
Li-Xin HUA
;
Chang-Jun YIN
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Antineoplastic Agents, Hormonal; therapeutic use; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; blood; Neoplasm Staging; Prostate-Specific Antigen; blood; Prostatectomy; methods; Prostatic Neoplasms; blood; drug therapy; pathology; surgery; Quality of Life; Retrospective Studies
- From: National Journal of Andrology 2014;20(12):1093-1097
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effect of adjuvant hormonal therapy (AHT) immediately after radical surgery for high- risk organ-confined or locally advanced prostate cancer using the PSA-related biochemical relapse rate within 2 years after surgery.
METHODSWe retrospectively analyzed 62 cases of high-risk organ-confined or locally advanced prostate cancer. The patients were treated by laparoscopic radical prostatectomy or radical retropubic prostatectomy after MRI and ECT systemic bone imaging examination, which revealed no regional lymph node or bone metastasis. Thirty-two of the patients (group A) received AHT orally or subcutaneously from 2 weeks to 1 months after operation, and another 30 (group B) were left untreated. We followed up the patients for 2 years, measuring the serum PSA level every 3 months, performing ECT every 6 months, and recording the adverse reactions, medication dura- tion, and the patients'quality of life.
RESULTSAll the operations were successfully accomplished. The rate of 2-year biochemical relapse-free survival was 78.13% (25/32) in group A and 53.33% (16/30) in group B.
CONCLUSIONAHT immediately after radical surgery can improve the rate of biochemical relapse-free survival of the patients with high-risk organ-confined or locally advanced prostate cancer and check the progression and metastasis of the disease.
